A new compound, 9-(3,4-dihydroxybutyl)guanine, has been synthesized and its antiherpes activity determined. 9-(3,4-Dihydroxybutyl)guanine was selectively phosphorylated by herpes simplex virus thymidine kinase and had a high affinity for this enzyme, with an inhibition constant of 1.5 ,uM. In cell culture, replication of different strains of herpes simplex virus types 1 and 2 was inhibited to the extent of 50%o by 4 to 18 ,uM (RS)-9-(3,4-dihydroxybutyl)guanine. The (R)-enantiomer of this compound was more inhibitory than the (S)-enantiomer. Herpesvirus DNA synthesis was selectively inhibited by (RS)-9-(3,4-dihydroxybutyl)guanine in infected cells, and a low cellular toxicity was observed. 
enantiomer of this compound was more inhibitory than the (S)-enantiomer. Herpesvirus DNA synthesis was selectively inhibited by (RS)-9-(3,4-dihydroxybutyl)guanine in infected cells, and a low cellular toxicity was observed. (RS)-9-(3,4-Dihydroxybutyl)guanine had a therapeutic effect when applied topically to guinea pigs with cutaneous herpes simplex type 1 infections and to rabbits with herpes keratitis. Oral treatment of a generalized herpes simplex type 2 infection in mice had a therapeutic effect.
Two principally different types of herpesvirus inhibitors have recently been designed. One utilizes herpes simplex virus (HSV) thymidine kinase (TK) to selectively phosphorylate the inhibitor which, after phosphorylation to a triphosphate, interferes with viral DNA synthesis. Both these steps are competitive reactions which depend on cellular concentrations of thymidine (dThd) and nucleoside triphosphates. Examples of this type of inhibitor are acyclovir (ACV) (11, 24) and bromovinyldeoxyuridine (4, 8) . The other principle for herpesvirus inhibitors can be exemplified by the noncompetitive inhibition of herpesvirus DNA polymerase by foscarnet (phosphonoformate) (12, 15, 23) and phosphonoacetate (5, 18, 20, 21) . In this case, the cellular concentrations of dThd and nucleoside triphosphates do not interfere with the antiherpes activity (25) .
A nucleoside analog that is useful as an antiherpes drug should preferably contain a normal base to decrease the risk of mutagenic effects and, in addition, if incorporated into DNA, should not allow chain elongation. ACV is a compound fulfilling these requirements (11, 24) and used for plaque assays as described previously (13, 25) . Most of the HSV-1 and HSV-2 strains used have been described previously (13, 15, 28) . The method used to determine viral and cellular DNA synthesis by 32p labeling and isodensity gradient centrifugation has been reported previously (18, 19) .
Effects on cell proliferation were determined as described previously (27) . The test compound was added to actively growing Vero, 3T3 (CCL92, mouse embryo) or Flow 5000 (human embryo) cells and incubated for 48 h. Cell numbers and volumes were measured by use of an electronic cell counter (Analysinstrument AB, Stockholm, Sweden).
Animal experiments. The method for inoculating the backs of guinea pigs with HSV-1, as well as the scoring system used to determine the therapeutic effect of treatment, have been described previously (3) . The herpes keratitis model, in which rabbits are inoculated in the cornea with HSV-1, has been described previously (2) . In the experiments with systemic herpes infections, NMRI mice weighing 14 to 15 g each were inoculated intraperitoneally with 104 PFU of HSV-2 strain 91075 as described by Kern et al. (17) .
RESULTS
Phosphorylation of DHBG by TKs. The phosphorylation rates by viral and cellular TK of (RS)-, (R)-, and (S)-DHBG at concentrations of 250 ,uM each were determined and compared with that of dThd (Table 1) . Owing to the sensitivity of the assay for measuring transfer of ly-32p from [y-32P]ATP to the tested compound, the Km values could not be determined. The (S)-enantiomer showed a lower amount of product formed, 46% of that obtained when dThd was used as substrate, whereas the amount of product formed for (RS)-and (R)-DHBG was about 74%. The explanation for the same rates of phosphorylation of (RS)-and (R)-DHBG is that the high concentration used was at the saturating level, and at this concentration the lower phosphorylation rate of (S)-in (RS)-DHBG was not detectable. No phosphorylation was detectable when cytosol TK was used for these compounds.
The affinity for HSV-1 TK and cytosol TK was determined in enzyme kinetic experiments. (RS)-DHBG was a competitive inhibitor of dThd phosphorylation, with a Ki value of 1.5 ,uM for HSV-1 TK (Fig. 2) . By replotting the data from the double-reciprocal plot, the Ki, (slope) and K (intersept) values could be determined (Fig. 2) . No difference in the affinity for the (R)-and (S)-enantiomer was detectable. When cytosol TK was used, (RS)-, (R)-, and (S)-DHBG all showed a K, of >250 ,uM (Table 1) . These results show that DHBG has a high and preferential affinity for HSV-1 TK as compared with cytosol TK and that DHBG can act as an alternative substrate for viral TK with a high phosphorylation rate.
Inhibition of herpesvirus multplication in cell culture by DHBG. The inhibition of HSV-1 and HSV-2 multiplication in cell cultures was determined at different concentrations of (RS)-DHBG, and the 50% inhibitory doses are shown in Table 2 . No major difference could be seen Cellular toxicity of DHBG. The effects of (RS)-DHBG on cellular proliferation were determined at concentrations of 100 and 500 pM (Table 3) . At 500 pM, (R)-and (RS)-DHBG gave 50% inhibition and (S)-DHBG gave 15% inhibition of Vero cell multiplication, whereas no effect on cell volume was observed (data not shown). Animal experiments with DHBG. The therapeutic effect of (RS)-DHBG on HSV-1 cutaneous infection in guinea pigs is shown in Fig. 4 . A 5% (wt/wt) (RS)-DHBG water-based cream was applied topically to infected skin areas, and the daily lesion score is shown for drug-and placebo cream-treated areas. (RS)-DHBG reduced the lesion score by 55%, and no skin irritation was observed.
Topical treatment of herpes keratitis in rabbits showed that 3% (wt/wt) (RS)-DHBG in an occulentum simplex formulation rapidly reduced the keratitis score (Fig. 5) . No irritation was observed in uninfected eyes treated with the 3% (wt/wt) (RS)-DHB3G formulation.
Mice inoculated intraperitoneally with HSV-2 were treated orally with 150 mg of (RS)-DHBG per kg of body weight per day for 10 days (Fig.  6 ). (RS)-DHBG reduced the mortality rate by 70%o, and no toxicity was observed. 
DISCUSSION
The three principal ideas behind the search for a new antiherpes agent are that it should be a nucleoside analog with a normal base, should compete well with dThd in selective phosphorylation by HSV TK, and should not be incorporated internally into DNA. These criteria appear to be met by the newly synthesized compound DHBG.
The phosphorylation of DHBG is a selective process carried out only by HSV TK (Table 1) . The observed Ki value for DHBG was about 115-fold lower than that observed for ACV, which was 173 ,uM (Larsson et al., in press). A small difference was seen between the rates of phosphorylation of the enantiomers, and it was highest for (R)-DHBG. In cell culture, both HSV-1 and HSV-2 multiplication (Table 2) were inhibited at concentrations of DHBG considerably lower than that causing inhibition of cell proliferation (Table 3) . The decreased inhibition of HSV strains either lacking TK or with a TK resistant to ACV shows that phosphorylation by HSV TK is an obligatory step in the inhibition of HSV multiplication by DHBG. A selective inhibition of HSV DNA synthesis in infected cells (Fig. 3) suggests that a phosphorylated form of DHBG selectively inhibits the viral DNA synthesis by analogy with inhibition by ACV (19) and foscarnet (18) . It remains to be seen whether DHBG will act as a chain terminator.
It should be noted that a compound such as foscarnet, which is not affected by the presence of dThd (25) , is considerably more effective for treatment of cutaneous HSV-1 infection in guinea pigs than is (RS)-DHBG or ACV, although it is less active in cell cultures (1) . A high dThd concentration has been observed in guinea pig skin (J. Harmenberg, personal communication), and it would be interesting to determine the dThd content of different organs in animals, including humans, since this could influence the efficacy of antiherpes drugs phosphorylated by viral TK.
A good therapeutic activity was found for (RS)-DHBG against herpes keratitis in rabbits (Fig. 5) (11, 24) , 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine (26), erythro-9-(2-hydroxy-3-nonyl)adenine (22) , and (S)-(2,3-dihydroxypropyl)adenine (9) have previously been investigated as antiherpes agents. The present study shows that other compounds of this type have antiviral activity.
A detailed analysis of the differences between (R)-and (S)-DHBG and their efficacies as compared with those of other compounds has yet to be carried out, but the present results show that DHBG has a definite potential as an antiherpes agent. The high affinity of DHBG for HSV TK will make this compound effective even in the presence of dThd. 
